These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 8306337

  • 1. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EG.
    Cancer Res; 1994 Feb 01; 54(3):749-55. PubMed ID: 8306337
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
    Withoff S, van der Zee AG, de Jong S, Hollema H, Smit EF, Mulder NH, de Vries EG.
    Br J Cancer; 1999 Feb 01; 79(5-6):748-53. PubMed ID: 10070864
    [Abstract] [Full Text] [Related]

  • 7. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA.
    Ann Clin Lab Sci; 1997 Feb 01; 27(6):402-12. PubMed ID: 9433537
    [Abstract] [Full Text] [Related]

  • 8. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M, Beck WT.
    Oncol Res; 1995 Feb 01; 7(2):103-11. PubMed ID: 7579726
    [Abstract] [Full Text] [Related]

  • 9. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH.
    Cancer Res; 1995 Apr 15; 55(8):1707-16. PubMed ID: 7712479
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
    Funayama Y, Nishio K, Takeda Y, Kubota N, Ohira T, Ohmori T, Ohta S, Ogasawara H, Hasegawa S, Saijo N.
    Anticancer Res; 1993 Apr 15; 13(6A):1981-8. PubMed ID: 8297104
    [Abstract] [Full Text] [Related]

  • 17. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW, Mirski SE, Cole SP, Sullivan DM.
    Cancer Res; 1994 Feb 01; 54(3):756-62. PubMed ID: 8306338
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS, Danks MK, Schmidt CA, Beck WT.
    Cancer Res; 1989 May 01; 49(9):2422-6. PubMed ID: 2539902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.